| |
HIV-infected Controls
|
HIV-infected
|
HIV-uninfected
| |
|---|
| |
Primary/Secondary Syphilis#
|
Latent Syphilis#
|
Primary/Secondary Syphilis#
|
PSS HIV+ vs. -, P$
|
|---|
|
Baseline
|
|
N
|
30
|
44
|
35
|
10
| |
|
Pro-inflammatory
|
|
IFNα
|
9.88 (1.6–16.43)
|
7.45 (0.8–31.35)
|
7.45 (0.8–20.42)
|
4.12 (0.8–24.73)
|
0.5202
|
|
IL1β
|
1.57 (1.57–1.57)
|
1.57 (1.57–1.57)
|
1.57 (1.57–1.57)
|
1.57 (1.57–1.57)
|
0.4883
|
|
IL-6
|
1.26 (1.26–1.26)
|
1.26 (1.26–1.26)*
|
1.26 (1.26–1.26)
|
1.26 (1.26–1.26)
|
0.722
|
|
IL-17A
|
1.52 (1.52–1.52)
|
1.52 (1.52–1.52)
|
1.52 (1.52–1.52)
|
1.52 (1.52–1.52)
|
0.8358
|
|
Th1
|
|
IFNγ
|
2.18 (1.54–4.59)
|
3.52 (1.54–5.45)
|
1.79 (1.54–4.59)
|
4.01 (1.54–16.66)
|
0.5991
|
|
IL-7
|
1.11 (1.11–1.11)
|
1.11 (1.11–1.36)
|
1.11 (1.11–1.11)
|
1.11 (1.11–1.11)
|
0.357
|
|
IL-12p40
|
1.02 (1.02–1.02)
|
1.02 (1.02–1.02)
|
1.02 (1.02–1.02)
|
1.02 (1.02–1.02)
|
0.4056
|
|
IL-12p70
|
1.61 (1.61–1.61)
|
1.61 (1.61–1.67)
|
1.61 (1.61–1.61)
|
1.61 (1.61–4.08)
|
0.6264
|
|
Chemokines
|
|
IL-8
|
1.6 (1.6–5.06)
|
4.51 (2.41–7.43)**
|
1.6 (1.6–3.15)
|
1.6 (1.6–5.13)
|
0.0723
|
|
IP-10
|
589.4 (319.38–917.05)
|
1016.1 (649.64–1451.32)**
|
696.89 (455.35–1101.67)
|
696.52 (426.27–1040.07)
|
0.1561
|
|
MCP-1
|
258.42 (179.09–307.75)
|
260.1 (216.95–307.35)
|
242.05 (180.35–303.1)
|
247.64 (205.76–287.32)
|
0.4321
|
|
MIP-1α
|
1.63 (1.63–3.65)
|
3.09 (1.63–8.3)
|
1.63 (1.63–1.63)
|
1.63 (1.63–1.63)
|
0.1247
|
|
MIP-1β
|
14.54 (0.99–22.23)
|
28.59 (16.06–42.51)**
|
15.2 (4.92–22.23)
|
8.46 (4.92–23.05)
|
0.0205
|
|
Th2
|
|
IL-4
|
1.58 (1.58–1.58)
|
1.58 (1.58–1.58)
|
1.58 (1.58–1.58)
|
1.58 (1.58–1.58)
|
0.4883
|
|
IL-5
|
1.58 (1.58–1.58)
|
1.58 (1.58–1.58)
|
1.58 (1.58–1.58)
|
1.58 (1.58–1.58)
|
0.3324
|
|
Anti-inflammatory
|
|
IL-10
|
1.55 (1.55–1.55)
|
25.3 (4.56–41.76)***
|
2.46 (1.55–4.62)*
|
2.73 (1.55–9.02)*
|
0.0029
|
|
6 month
|
|
N
| |
41
|
34
|
10
| |
|
Pro-inflammatory
|
|
IFNα
| |
0.8 (0.8–9.27)**#
|
0.8 (0.8–7.8)**#
|
0.8 (0.8–0.8)*#
|
0.3282
|
|
IL-1β
| |
1.57 (1.57–1.57)
|
1.57 (1.57–1.57)
|
1.57 (1.57–1.57)
|
0.1798
|
|
IL-6
| |
1.26 (1.26–1.26)
|
1.26 (1.26–1.26)
|
1.26 (1.26–1.26)
|
0.7379
|
|
IL-17A
| |
1.52 (1.52–1.52)
|
1.52 (1.52–1.52)
|
1.52 (1.52–1.52)
|
0.7379
|
|
Th1
|
|
IFNγ
| |
1.54 (1.54–5.09)
|
1.62 (1.54–4.88)
|
5.17 (1.54–13.89)
|
0.0978
|
|
IL-7
| |
1.11 (1.11–1.11)
|
1.11 (1.11–1.11)
|
1.11 (1.11–1.11)
|
0.6486
|
|
IL-12p40
| |
1.02 (1.02–1.02)
|
1.02 (1.02–1.02)
|
1.02 (1.02–1.02)
|
0.2068
|
|
IL-12p70
| |
1.61 (1.61–1.61)
|
1.61 (1.61–1.86)
|
1.61 (1.61–1.61)
|
0.7639
|
|
Chemokines
|
|
IL-8
| |
1.87 (1.6–4.02)
|
1.6 (1.6–1.7)
|
1.66 (1.6–3.75)
|
0.4406
|
|
IP-10
| |
564.56 (392.18–740.03)
|
592.04 (447.8–831.96)
|
447 (309–593)
|
0.2134
|
|
MCP-1
| |
270.25 (225.5–330.3)
|
261.32 (241.06–312.26)
|
269 (219–297)
|
0.8287
|
|
MIP-1α
| |
1.63 (1.63–1.63)
|
1.63 (1.63–1.63)
|
1.63 (1.63–1.63)
|
0.6726
|
|
MIP-1β
| |
7.4 (0.99–20.28)
|
9.17 (1.99–14)
|
2.39 (0.99–12.05)
|
0.249
|
|
Th2
|
|
IL-4
| |
1.58 (1.58–1.58)
|
1.58 (1.58–1.58)
|
1.58 (1.58–1.58)
|
0.1798
|
|
IL-5
| |
1.58 (1.58–1.58)
|
1.58 (1.58–1.58)
|
1.58 (1.58–1.58)
|
0.3621
|
|
Anti-inflammatory
|
|
IL-10
| |
1.83 (1.83–4.09)***
|
2.11 (1.83–3.37)***
|
2.26 (1.83–4.46)**
|
0.6296
|
- All values are median and interquartile range. Data are n (%), median (IQR), unless otherwise stated
-
#
P-value is for comparison with controls at baseline (Mann-Whitney U-test)
-
$
P-value is for comparison between HIV-infected and uninfected groups with Primary/Secondary syphilis (Mann-Whitney U-test)
- *P < 0.05, ** P < 0.005, ***P < 0.0005
- PSS - Primary/Secondary Syphilis
